Navigating the Evolving Treatment Landscape in HER2-mutated NSCLC - Episode 10

First-in-Human Study of BAY2927088 in Advanced HER2-Mutated NSCLC

May 15, 2024

Edgardo S. Santos Castillero, MD, FACP, FASCO, Martin Dietrich, MD, PhD, Edward S. Kim, MD, MBA, Lyudmila A. Bazhenova, MD, D. Ross Camidge, MD, PhD

Martin Dietrich, MD, PhD, provides an overview of the first-in-human study of BAY2927088, a novel TKI, in patients with advanced HER2-mutated non–small cell lung cancer.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Diagnosing HER2-mutated NSCLC

EP. 2: Biomarker Testing Challenges in HER2-mutated NSCLC

EP. 3: Role of ADCs in HER2-Mutated NSCLC

EP. 4: DESTINY-Lung01 & DESTINY-Lung02: T-DXd in Metastatic HER2-Mutated NSCLC

EP. 5: The Role of Trastuzumab Deruxtecan in HER2-Mutated NSCLC

EP. 6: DESTINY-Lung04: First-Line Trastuzumab Deruxtecan in HER2-Mutated NSCLC

EP. 7: Managing Adverse Events Associated With ADCs in HER2-Mutated NSCLC

EP. 8: The Potential Role of TKIs in HER2-Mutated NSCLC

EP. 9: Beamion LUNG-1: Zongertinib in Advanced HER2-Mutated NSCLC

Now Viewing

EP. 10: First-in-Human Study of BAY2927088 in Advanced HER2-Mutated NSCLC

EP. 11: Adverse Events Associated With TKIs in HER2-Mutated NSCLC

EP. 12: Challenges and Unmet Needs in HER2-Mutated NSCLC

EP. 13: Treatment Considerations in HER2-Mutated NSCLC

EP. 14: Key Takeaways in HER2-Mutated NSCLC